AI Engines For more Details: Perplexity Kagi Labs You
Mechanism of Action: Guanadrel sulfate belongs to a class of medications known as sympatholytics or adrenergic neuron blockers. It works by inhibiting the release of norepinephrine from nerve endings, which reduces sympathetic nervous system activity. This leads to vasodilation (widening of blood vessels) and a subsequent decrease in blood pressure.
Treatment of Hypertension: Guanadrel sulfate was historically used as an antihypertensive medication to lower blood pressure in patients with essential hypertension (high blood pressure without an identifiable cause). It was particularly useful in patients who did not respond adequately to other antihypertensive agents.
Limited Use: Despite its efficacy in lowering blood pressure, guanadrel sulfate is rarely used today due to several limitations and side effects associated with its use. These include the need for frequent dosing, slow onset of action, and a high incidence of adverse effects.
Adverse Effects: Guanadrel sulfate can cause a range of side effects, some of which can be severe. Common side effects include orthostatic hypotension (a sudden drop in blood pressure upon standing), dizziness, lightheadedness, weakness, fatigue, gastrointestinal disturbances (such as nausea and diarrhea), and sexual dysfunction.
Orthostatic Hypotension: Orthostatic hypotension is one of the most significant side effects of guanadrel sulfate. It occurs due to the medication's ability to reduce sympathetic tone, leading to inadequate compensation for changes in body position. Patients may experience symptoms such as dizziness, lightheadedness, or fainting when transitioning from lying down to standing up.
Central Nervous System Effects: Guanadrel sulfate can cross the blood-brain barrier and exert effects on the central nervous system. This may result in side effects such as sedation, confusion, depression, and cognitive impairment.
Cardiovascular Effects: In addition to lowering blood pressure, guanadrel sulfate may also affect heart rate and rhythm. It can cause bradycardia (slow heart rate) and may exacerbate conduction abnormalities in patients with pre-existing cardiac conditions.
Withdrawal Rebound Hypertension: Abrupt discontinuation of guanadrel sulfate can lead to rebound hypertension, characterized by a sudden and significant increase in blood pressure. Therefore, the medication should be tapered off gradually under medical supervision when discontinuing treatment.
Contraindications and Precautions: Guanadrel sulfate is contraindicated in patients with hypersensitivity to the medication, severe bradycardia, heart block, or pheochromocytoma (a rare adrenal gland tumor). It should be used with caution in patients with pre-existing cardiovascular disease, renal impairment, or hepatic impairment.
Interactions with Other Medications: Guanadrel sulfate may interact with other medications that affect blood pressure or sympathetic nervous system activity. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking before starting guanadrel sulfate.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.4 | -0.4 | |
ADHD | 3.7 | 0.4 | 8.25 |
Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.1 | 5 |
Allergic Rhinitis (Hay Fever) | 0.9 | 2 | -1.22 |
Allergies | 5.5 | 0.9 | 5.11 |
Allergy to milk products | 1 | 0.9 | 0.11 |
Alopecia (Hair Loss) | 1.5 | 1.5 | |
Alzheimer's disease | 2.3 | 3 | -0.3 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 0.7 | 1.43 |
Ankylosing spondylitis | 3.7 | 0.4 | 8.25 |
Anorexia Nervosa | 0.1 | 1 | -9 |
Antiphospholipid syndrome (APS) | 1.3 | 1.3 | |
Asthma | 1.2 | 0.4 | 2 |
Atherosclerosis | 0.9 | 0.8 | 0.13 |
Atrial fibrillation | 2.3 | 1.1 | 1.09 |
Autism | 5.7 | 5.1 | 0.12 |
Barrett esophagus cancer | 0.5 | 0.3 | 0.67 |
benign prostatic hyperplasia | 0.4 | 0.4 | |
Bipolar Disorder | 0.7 | 1 | -0.43 |
Brain Trauma | 0.9 | 0.4 | 1.25 |
Carcinoma | 3.3 | 2.3 | 0.43 |
Celiac Disease | 2.1 | 3 | -0.43 |
Cerebral Palsy | 1.2 | 0.9 | 0.33 |
Chronic Fatigue Syndrome | 4.5 | 4.6 | -0.02 |
Chronic Kidney Disease | 1.4 | 0.8 | 0.75 |
Chronic Lyme | 0.4 | -0.4 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 0.2 | 8.5 |
Chronic Urticaria (Hives) | 1.9 | 0.3 | 5.33 |
Coagulation / Micro clot triggering bacteria | 1.5 | 1 | 0.5 |
Colorectal Cancer | 3.5 | 0.9 | 2.89 |
Constipation | 0.8 | 0.7 | 0.14 |
Coronary artery disease | 0.7 | 0.9 | -0.29 |
COVID-19 | 10.3 | 9 | 0.14 |
Crohn's Disease | 5.3 | 2.9 | 0.83 |
cystic fibrosis | 1.1 | 0.8 | 0.38 |
deep vein thrombosis | 1.1 | 0.5 | 1.2 |
Depression | 7.4 | 5.4 | 0.37 |
Dermatomyositis | 0.3 | 0.4 | -0.33 |
Eczema | 1 | 1.9 | -0.9 |
Endometriosis | 3 | 0.7 | 3.29 |
Eosinophilic Esophagitis | 0 | 0.4 | 0 |
Epilepsy | 2.5 | 1.5 | 0.67 |
Fibromyalgia | 1.5 | 1 | 0.5 |
Functional constipation / chronic idiopathic constipation | 4.1 | 1.9 | 1.16 |
gallstone disease (gsd) | 1.8 | 0.7 | 1.57 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 1.2 | -0.2 |
Generalized anxiety disorder | 1.8 | 1.4 | 0.29 |
giant cell arteritis | 0.1 | -0.1 | |
Glioblastoma | 0.3 | -0.3 | |
Graves' disease | 1.2 | 1.6 | -0.33 |
Halitosis | 0.7 | 0.3 | 1.33 |
Hashimoto's thyroiditis | 1.9 | 0.6 | 2.17 |
Hidradenitis Suppurativa | 0.3 | 0.4 | -0.33 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.9 | 0.6 | 3.83 |
hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
hyperglycemia | 0.4 | 1.2 | -2 |
Hyperlipidemia (High Blood Fats) | 0.9 | 0.5 | 0.8 |
hypersomnia | 0.5 | -0.5 | |
hypertension (High Blood Pressure | 1.9 | 3.9 | -1.05 |
Hypothyroidism | 1.2 | -1.2 | |
Hypoxia | 0.3 | 0.3 | |
IgA nephropathy (IgAN) | 1.9 | -1.9 | |
Inflammatory Bowel Disease | 4.1 | 3.7 | 0.11 |
Insomnia | 0.9 | 0.4 | 1.25 |
Intelligence | 0.4 | 0.4 | |
Intracranial aneurysms | 0.8 | 0.5 | 0.6 |
Irritable Bowel Syndrome | 3.1 | 2.8 | 0.11 |
Liver Cirrhosis | 3.2 | 2 | 0.6 |
Long COVID | 4.9 | 6.1 | -0.24 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 0.9 | 0.9 | 0 |
ME/CFS with IBS | 0.7 | 2.3 | -2.29 |
ME/CFS without IBS | 1.7 | 2 | -0.18 |
Menopause | 2.4 | 2.4 | |
Metabolic Syndrome | 6.3 | 5.7 | 0.11 |
Mood Disorders | 8.9 | 5.8 | 0.53 |
multiple chemical sensitivity [MCS] | 1.6 | 0.5 | 2.2 |
Multiple Sclerosis | 4.7 | 1.4 | 2.36 |
Multiple system atrophy (MSA) | 1 | 0.8 | 0.25 |
Neuropathy (all types) | 0.7 | 0.4 | 0.75 |
neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.1 | 3.8 | -0.81 |
NonCeliac Gluten Sensitivity | 0.4 | -0.4 | |
Obesity | 6.8 | 3.5 | 0.94 |
obsessive-compulsive disorder | 5.4 | 2 | 1.7 |
Osteoarthritis | 1.1 | 1.1 | |
Osteoporosis | 1.4 | 0.7 | 1 |
pancreatic cancer | 0.5 | 0.5 | |
Parkinson's Disease | 2.4 | 2.3 | 0.04 |
Polycystic ovary syndrome | 1.4 | 0.9 | 0.56 |
Postural orthostatic tachycardia syndrome | 0.1 | 0.4 | -3 |
Premenstrual dysphoric disorder | 1.3 | 0.1 | 12 |
primary biliary cholangitis | 0.4 | 0.8 | -1 |
Psoriasis | 4.5 | 0.7 | 5.43 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.5 | 2.8 | 0.61 |
Rosacea | 0.6 | 0.3 | 1 |
Schizophrenia | 4.7 | 1.1 | 3.27 |
Sjögren syndrome | 2.7 | 2.8 | -0.04 |
Sleep Apnea | 0.9 | 1.2 | -0.33 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 0.7 | 0.57 |
Stress / posttraumatic stress disorder | 2.2 | 2 | 0.1 |
Systemic Lupus Erythematosus | 2.9 | 1.3 | 1.23 |
Tic Disorder | 0.5 | 1.3 | -1.6 |
Tourette syndrome | 0.2 | -0.2 | |
Type 1 Diabetes | 2.8 | 1.6 | 0.75 |
Type 2 Diabetes | 6.5 | 4.1 | 0.59 |
Ulcerative colitis | 3.1 | 2.6 | 0.19 |
Unhealthy Ageing | 3.3 | 0.9 | 2.67 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.